Urethral metastasis of bladder cancer after surgery is rare. We present a 63-year-old man who had surgery for invasive bladder carcinoma and prostate adenocarcinoma 4 years ago and referred for urethral hemorrhage. 18 F-FDG PET/CT was performed for restaging and showed intense linear 18 F-FDG activity in the proximal urethra. The patient underwent urethrectomy, and histopathology determined urethral metastasis.
Disease burden is a critical determinant of outcomes in CAR-T therapy for B-cell lymphomas, and one of the most widely used techniques for its assessment is Total Metabolic Tumor Volume (TMTV) measured via [F]FDG PET/CT. Biological parameters may further refine the risk profile. We analyzed baseline [F]FDG PET/CT scans from 40 patients treated with CAR-T, using an AI-based automated segmentation algorithm to determine TMTV.
Background: Radiotherapy with or without concurrent chemotherapy is a standard of care treatment for patients with head and neck squamous cell carcinoma (HNSCC). Upon completion, patients are referred for a post-treatment F-FDG PET/CT (Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography) scan to help guide ongoing management by assessing for the presence or absence of residual or recurrent disease and differentiating this from post-treatment inflammation. To improve objective reporting of response, we developed the Christie score.
Purpose: PET imaging is a pivotal tool for biomarker research aimed at personalized medicine. Leveraging the quantitative nature of PET requires knowledge of plasma radiotracer concentration. Typically, the arterial input function (AIF) is obtained through arterial cannulation, an invasive and technically demanding procedure.
Objective: Overexpression of Human Epidermal Growth Factor Receptor 2 (HER2) is thought to be more aggressive in gastric cancer. This study aimed to evaluate the predictability of HER2 status and other prognostic pathologic parameters using [F]FDG PET/CT and to investigate its impact on survival.
Methods: Pretreatment metabolic parameters measured by [F]FDG PET/CT as a prognostic factor were retrospectively evaluated in 117 HER2-analysed patients.
Department of Translational Imaging in Oncology, National Center for Tumor Diseases (NCT/UCC) Dresden, Medical Faculty and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74, Dresden, 01307, Germany.
Purpose: Staging of non-small cell lung cancer (NSCLC) is commonly based on [F]FDG PET/CT, in particular to exclude distant metastases and guide local therapy approaches like resection and radiotherapy. Although it is hoped that PET/CT will increase the value of primary staging compared to conventional imaging, it is generally limited to the characterization of TNM. The first aim of this study was to evaluate the PET parameter metabolic tumor volume (MTV) above liver background uptake as a prognostic marker in lung cancer.
